Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides a one-stop solution for LY9-CART development. Our product line covers a wide range of anti-LY9 CAR-T vectors, viruses, cells, and reagents designed to facilitate your research. Please browse the list below to find the products you need.
Ly-9, known as CD229, is a cell surface glycoprotein found on thymocytes, mature T and B cells, and NK cell subpopulations. LY9 is involved in many important processes, such as serving as a negative regulator of the development and homeostasis of thymus innate cell, and maintaining immune cell tolerance. Studies showed that LY9 is a useful prognostic biomarker and an attractive therapeutic target for many diseases.
Associated Diseases
Anti-LY9 CAR-T Expression Test
In order to help our customers quickly identify the expression of specific CAR, we have developed a series of CAR detection reagents (e.g., sensitive fluoresce conjugated CAR detection products, Linker-targeted antibodies), as well as multiple experimental services for CAR expression verification via various approaches, such as qPCR, WB, flow cytometry.
Anti-LY9 CAR-T Proliferation Test
The verification of CART cell viability and proliferation is a very necessary test, which will provide an important reference for the subsequent CART function. Creative Biolabs conducts a variety of sensitive proliferation assays for CART cells, including MTT assay, CCK-8 assay, and CFSE-based test.
Fig.1 Expansion test of LY9 CAR-T cells detected by automated cell counting.1
Anti-LY9 CAR-T Cytokine Release Test
Cytokine production and release is an important manifestation in the incubation process of CART cells and tumor cells. Creative Biolabs offers various robust detection assays to assess cytokine production and release, including multiplex bead arrays, enzyme-linked immunosorbent assays (ELISAs), and flow-based intracellular cytokine tests.
Fig.2 Cytokine secretion test of LY9 CAR-T cells co-cultured with primary plasma cell leukemia cells detected by cytometric bead assay.1
Anti-LY9 CAR-T In Vitro Cytotoxicity Assay
In vitro cytotoxicity assay is designed to preliminarily verify the cytotoxic potential and specificity of CAR-T cells, providing many important references for further in vivo validation. We have developed a variety of methods for global customers to select the type that suits their project needs, including luciferase-based cytotoxicity test, flow cytometry cytotoxicity test, and real-time cell analysis (RTCA).
Fig.3 Cytotoxic activity test of LY9-CART cells against K562-CD229 tumor cells detected by luciferase-based cytotoxicity assay at indicated E: T ratio.1
Anti-LY9 CAR-T Cell Therapy Animal Models
To meet the diverse needs of our customers' CART projects, we offer a range of animal models for anti-LY9 CART cell in vivo tests, including humanized, syngeneic, and xenograft models. These animal models are convenient for customers to quickly establish experimental schemes suitable for their projects, greatly speeding up the process of projects.
Efficacy Test of Anti-LY9 CAR-T
For in vivo efficacy testing of anti-LY9 CAR-T, Creative Biolabs has launched a variety of effective evaluation tests to assist in customers' projects, including but not limited to bioluminescence imaging, and in vivo dynamic analysis.
Fig.4 In vivo efficacy test of LY9 CAR-T cells in U-266 xenograft mouse model by BLI detection (Left panel) and survival record (Right panel).1
Toxicity Evaluation Anti-LY9 CAR-T
To monitor the toxicity of LY9-CART treatment, such as the targeting of healthy LY9 expressing cells by LY9 CAR T cells, we provide various approaches to identify and characterize potential adverse events associated with the CART therapy, including phenotype analysis of in vivo model samples, off-toxicity studies, etc.
Fig.5 B-cell numbers analysis of the mouse models' peripheral blood (g) and bone marrow (h) after CART treatment.1
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-YJ1282 | Anti-LY9 (2F2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 2F2 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-YJ1577 | Anti-LY9 (2F2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2F2 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7065 | Anti-LY9 (HLy9.25) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | HLy9.25 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7069 | Anti-LY9 (CBXC-2877) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2877 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7080 | Anti-LY9 (CBXC-1043) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBXC-1043 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7093 | Anti-LY9 (Hly9.1.25) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Hly9.1.25 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7545 | Anti-LY9 (HLy9.25) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | HLy9.25 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7549 | Anti-LY9 (CBXC-2877) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-2877 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7560 | Anti-LY9 (CBXC-1043) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBXC-1043 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CQ7573 | Anti-LY9 (Hly9.1.25) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Hly9.1.25 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY7271 | Anti-LY9 (CBFYC-0474) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-0474 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY7272 | Anti-LY9 (CBFYC-2931) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2931 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY7273 | Anti-LY9 (CBFYC-2932) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2932 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY8069 | Anti-LY9 (CBFYC-0474) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-0474 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY8070 | Anti-LY9 (CBFYC-2931) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2931 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WFY8071 | Anti-LY9 (CBFYC-2932) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYC-2932 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-WJ4715 | Anti-LY9 (CBWJC-4127) h(41BB-CD3ζ) CAR, pCDCAR1 | Mouse | CBWJC-4127 | Hamster | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX255 | Anti-LY9 (X11X255) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X255 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX653 | Anti-LY9 (X11X255) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X255 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX1051 | Anti-LY9 (X11X255) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X255 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
